Drug Trial Radar · NCT07662109
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,000
Planned (sponsor's estimate)
Start
Jul 6, 2026
Primary completion
Jul 5, 2028
Study completion Jul 5, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jun 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.
Conditions
- Type 2 Diabetes Mellitus
Interventions
ElecoglipronDrug
Elecoglipron is administered orally once daily.
DapagliflozinDrug
Dapagliflozin administered orally once daily.
Elecoglipron-matched placeboDrug
A placebo matching elecoglipron administered orally once daily.
Dapagliflozin-matched placeboDrug
A placebo matching dapagliflozin administered orally once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Hemoglobin A1c (HbA1c)Time frame: Baseline to Week 40
Locations
303 sites in 24 countries. Site status is shown where the registry gives one.
Research Site
Huntsville, Alabama · Not yet recruiting
Research Site
Mobile, Alabama · Not yet recruiting
Research Site
Sheffield, Alabama · Not yet recruiting
Research Site
Little Rock, Arkansas · Recruiting
Research Site
Bakersfield, California · Not yet recruiting
Research Site
Los Angeles, California · Recruiting
Research Site
Ontario, California · Not yet recruiting
Research Site
Lake City, Florida · Recruiting
Research Site
Lakeland, Florida · Recruiting
Research Site
Atlanta, Georgia · Not yet recruiting
Research Site
Chicago, Illinois · Recruiting
Research Site
Skokie, Illinois · Not yet recruiting
Research Site
Evansville, Indiana · Not yet recruiting
Research Site
Sioux City, Iowa · Not yet recruiting
Research Site
Zachary, Louisiana · Not yet recruiting
Research Site
Annapolis, Maryland · Not yet recruiting
Research Site
Lutherville-Timonium, Maryland · Not yet recruiting
Research Site
Oxon Hill, Maryland · Recruiting
Research Site
Boston, Massachusetts · Not yet recruiting
Research Site
Boston, Massachusetts · Not yet recruiting
Research Site
Troy, Michigan · Recruiting
Research Site
Ridgeland, Mississippi · Recruiting
Research Site
Elkhorn, Nebraska · Not yet recruiting
Research Site
Toms River, New Jersey · Not yet recruiting
Research Site
Albuquerque, New Mexico · Recruiting
Research Site
Brooklyn, New York · Recruiting
Research Site
Rosedale, New York · Not yet recruiting
Research Site
Raleigh, North Carolina · Not yet recruiting
Research Site
Beachwood, Ohio · Not yet recruiting
Research Site
Maumee, Ohio · Recruiting
Research Site
Norman, Oklahoma · Not yet recruiting
Research Site
Philadelphia, Pennsylvania · Not yet recruiting
Research Site
Kingsport, Tennessee · Recruiting
Research Site
Nashville, Tennessee · Recruiting
Research Site
Dallas, Texas · Recruiting
Research Site
McKinney, Texas · Not yet recruiting
Research Site
Paris, Texas · Recruiting
Research Site
San Antonio, Texas · Not yet recruiting
Research Site
Webster, Texas · Withdrawn
Research Site
Layton, Utah · Not yet recruiting
Showing 40 of 303 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.